Page 18 - 《中国药房》2025年11期
P. 18

fluence of hepatic impairment on everolimus pharmacoki‐  [60]  OLIVEIRA M,RUGO H S,HOWELL S J,et al. Capiva-
               netics:implications for dose adjustment[J]. Clin Pharma‐  sertib and fulvestrant for patients with hormone receptor-
               col Ther,2001,70(5):425-430.                        positive,HER2-negative  advanced  breast  cancer (CAPI‐
          [49]  ROYER B,KADERBHAÏ C G,SCHMITT A. Pharmaco‐         tello-291):patient-reported outcomes from a phase 3,ran‐
               kinetics and pharmacodynamic of alpelisib[J]. Clin Phar‐  domised,double-blind,placebo-controlled trial[J]. Lancet
               macokinet,2023,62(1):45-53.                         Oncol,2024,25(9):1231-1244.
          [50]  中国抗癌协会肿瘤药物临床研究专业委员会,国家肿瘤                      [61]  XU K Y,SHAMEEM R,WU S H. Risk of hyperglycemia
               质控中心乳腺癌专家委员会,中国抗癌协会肿瘤病理专                            attributable  to  everolimus  in  cancer  patients:a  meta-
               业委员会,等 . PI3K/AKT/mTOR 信号通路抑制剂治疗                    analysis[J]. Acta Oncol. 2016,55(9/10):1196-1203.
               乳腺癌临床应用专家共识[J]. 中华肿瘤杂志,2022,44                 [62]  FDA.  Drug  development  and  drug  interactions  table  of
              (7):673-692.                                         substrates,inhibitors and inducers[EB/OL]. [2024-11-08].
          [51]  DE MORAES F C A,SANO V K T,PEREIRA C R M,          https://www.fda.gov/drugs/drug-interactions-labeling/drug-
               et al. Treatment-related adverse events in patients with ad‐  development-and-drug-interactions-table-substrates-inhibi-
               vanced breast cancer receiving adjuvant AKT inhibitors:a   tors-and-inducers.
               meta-analysis  of  randomized  controlled  trials[J].  Eur  J   [63]  GEBBIA V,BELLAVIA G,FERRAÙ F,et al. Adherence,
               Clin Pharmacol,2024,80(9):1373-1385.                compliance and persistence to oral antineoplastic therapy:
          [52]  周慧,海广范,张涛,等 . 癌症治疗中 PI3K/AKT/mTOR                  a review focused on chemotherapeutic and biologic agents
               通路及靶向抑制剂研究进展[J]. 中国药业,2023,32(5):                   [J]. Expert Opin Drug Saf,2012,11(Supp. 1):S49-S59.
               127-135.                                       [64]  李朋梅,张明,张相林. 依维莫司的药动学影响因素及治
          [53]  郑范丽,郑亚楠,黄莉莉,等 . PI3Kδ 抑制剂在 B 细胞淋                   疗药物监测研究进展[J]. 中国药房,2013,24(46):4383-
               巴瘤中的应用情况[J]. 中国现代应用药学,2024,41(6):                   4386.
               847-857.                                       [65]  魏春岚,袁长蓉. 肿瘤患者口服化疗药物依从性测量工
          [54]  PENG D S,HUANG B Q,NING H T,et al. Efficacy and    具的研究进展[J]. 护理学杂志,2014,29(2):89-91.
               safety  of  PI3K/Akt/mTOR  inhibitors  combined  with   [66]  RESHMA V,CHACKO A M,ABDULLA N,et al. Medi‐
               trastuzumab  therapy  for  HER2-positive  breast  cancer:a   cation  adherence  in  cancer  patients:a  comprehensive  re‐
               meta-analysis[J].  Eur  Rev  Med  Pharmacol  Sci,2022,26  view[J]. Cureus,2024,16(1):e52721.
              (20):7667-7678.                                 [67]  魏春岚,袁长蓉. 肿瘤患者口服化疗药物依从性的影响
          [55]  SHAN  W  H,WU  G  X,HUANG  Y  T,et  al.  Adverse   因素及干预研究进展[J]. 中国护理管理,2014,14(9):
               events  in  lymphoma  patients  treated  with  phosphoinosi-   998-1001.
               tide 3 kinase inhibitor in clinical trials:a meta-analysis[J].   [68]  AVERY  A  J,RODGERS  S,CANTRILL  J  A,et  al.  A
               Ann Hematol,2022,101(8):1741-1753.                  pharmacist-led  information  technology  intervention  for
          [56]  XU H C,WANG Y,HAN Y Q,et al. CDK4/6 inhibitors     medication  errors (PINCER):a  multicentre,cluster  ran‐
               versus  PI3K/AKT/mTOR  inhibitors  in  women  with  hor‐  domised,controlled  trial  and  cost-effectiveness  analysis
               mone  receptor-positive,HER2-negative  metastatic  breast   [J]. Lancet,2012,379(9823):1310-1319.
               cancer:an updated systematic review and network meta-  [69]  BLUM  M  R,SALLEVELT  B  T  G  M,SPINEWINE A,
               analysis  of  28  randomized  controlled  trials[J].  Front  On‐  et al. Optimizing therapy to prevent avoidable hospital ad‐
               col,2022,12:956464.                                 missions in multimorbid older adults (OPERAM):cluster
          [57]  LEUNG J H,LEUNG H W C,WANG S Y,et al. Efficacy     randomised controlled trial[J]. BMJ,2021,374:n1585.
               and safety of CDK4/6 and PI3K/AKT/mTOR inhibitors as   [70]  田欣,闫雪莲,梅丹,等. 全国医疗机构药物重整服务规
               second-line treatment in postmenopausal patients with hor‐  范化开展情况的调查研究[J]. 中国药房,2024,35(10):
               mone receptor-positive,HER-2-negative metastatic breast   1163-1167.
               cancer:a network meta-analysis[J]. Expert Opin Drug Saf,  [71]  都丽萍,梅丹,张波,等.用药教育标准制订与解析[J].医
               2021,20(8):949-957.                                 药导报,2022,41(11):1635-1638.
          [58]  RUGO  H  S,ANDRÉ  F,YAMASHITA  T,et  al.  Time   [72]  四川省医学科学院·四川省人民医院药学部,中华医学
               course and management of key adverse events during the   会临床药学分会,童荣生,等. 临床药学服务价值评价实
               randomized  phase  Ⅲ  SOLAR-1  study  of  PI3K  inhibitor   践指南:第1版[J]. 医药导报,2024,43(3):321-333.
               alpelisib plus fulvestrant in patients with HR-positive ad‐  [73]  国家肿瘤质控中心乳腺癌专家委员会,北京乳腺病防治
               vanced breast cancer[J]. Ann Oncol,2020,31(8):1001-  学会健康管理专业委员会. 中国乳腺癌随诊随访与健康
               1010.                                               管理指南:2022版[J]. 中华肿瘤杂志,2022,44(1):1-28.
          [59]  SHEN S,CHEN Y,CARPIO A,et al. Characterization of           (收稿日期:2024-12-12  修回日期:2025-04-19)
               alpelisib-associated  hyperglycemia  in  metastatic  breast                        (编辑:刘明伟)
               cancer[J]. J Clin Oncol,2022,40(Supp. 16):1016.




          · 1300 ·    China Pharmacy  2025 Vol. 36  No. 11                            中国药房  2025年第36卷第11期
   13   14   15   16   17   18   19   20   21   22   23